Selection of Systemic Therapy: Chemotherapy and Androgen Axis Agents

Selection of Systemic Therapy: Chemotherapy and Androgen Axis Agents

Evan Yu, MD compares data from the CHAARTED and GETUG-AFU 15 trials, including safety and toxicity considerations, and discusses which patients should receive docetaxel.

Evan Y. Yu, MD
Associate Professor of Medicine (Oncology)
University of Washington
Fred Hutchinson Cancer Research Center


SEE RELATED CONTENT

Insights into E3805: The CHAARTED trial - Abstract